The Safety and Clinical Effects of Amisulpride in Children and Adolescents with Psychiatric Disorders: A Case Series.

IF 1.5 4区医学 Q2 PEDIATRICS

Journal of child and adolescent psychopharmacology Pub Date : 2025-02-17 DOI:10.1089/cap.2024.0139

Osman Özdemir

引用次数: 0

Abstract

Objectives: The objective of this study was to explore the safety and clinical effects of amisulpride in children and adolescents with psychiatric disorders. Methods: This case series included six patients, aged 11 to 19 years, diagnosed with affective disorder, autism, anxiety, psychosis, and obsessive-compulsive disorder, and treated with amisulpride at doses ranging from 100 to 400 mg per day. Results: Amisulpride appeared to reduce psychotic and behavioral symptoms. Observed side effects included increased appetite, weight gain, sedation, and mild extrapyramidal symptoms. Conclusion: Amisulpride may have promise for study and future use in children and adolescents with psychiatric disorders and severe symptoms.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of child and adolescent psychopharmacology 医学-精神病学

CiteScore

3.60

自引率

5.30%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Child and Adolescent Psychopharmacology (JCAP) is the premier peer-reviewed journal covering the clinical aspects of treating this patient population with psychotropic medications including side effects and interactions, standard doses, and research on new and existing medications. The Journal includes information on related areas of medical sciences such as advances in developmental pharmacokinetics, developmental neuroscience, metabolism, nutrition, molecular genetics, and more. Journal of Child and Adolescent Psychopharmacology coverage includes: New drugs and treatment strategies including the use of psycho-stimulants, selective serotonin reuptake inhibitors, mood stabilizers, and atypical antipsychotics New developments in the diagnosis and treatment of ADHD, anxiety disorders, schizophrenia, autism spectrum disorders, bipolar disorder, eating disorders, along with other disorders Reports of common and rare Treatment Emergent Adverse Events (TEAEs) including: hyperprolactinemia, galactorrhea, weight gain/loss, metabolic syndrome, dyslipidemia, switching phenomena, sudden death, and the potential increase of suicide. Outcomes research.